dramat better expect
report stronger anticip result revenu non-gaap ep
 consensu estim respect mainli driven
strong mavyret sale hepat hcv made follow chang model
result updat po vs hcv sale forecast increas
peak vs base strong launch
manag commentari detail improv oper margin
larg due lower sg base increas confid abbv abil
deliv oper margin target non-gaap tax rate
vs thereaft new price-to-earnings multipl
take account stronger ep growth valu use blend
valuat risk-adjust dcf price-to-earnings reiter buy rate strong
mavyret launch anticip acceler dividend growth share buyback
increas appreci pipelin addit clinic readout
takeaway call
focu result updat effect tax rate migrat
subsequ period came well expect slight
improv investor feedback suggest tax outlook meaning better
street expect key driver share appreci base
discuss compani believ abbv structur patent-rel tax
strategi uniqu henc caution investor reading-through
similar magnitud rate reduct us major mavyret launch came well
ahead our/street expect global us cover live
pariti competitor product expect sale peak broader adopt
forecast mid high singl digit eros reflect declin number
elig pt capit deploy larg reiter recent comment indic
acceler capit deploy dividend share buy-back
focus asset drive growth period venclexta file
approv acut myeloid leukemia patient elig chemotherapi
ahead expect given strong data phase studi
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
research-bas global pharmaceut
busi spun abbott
develop market drug area
immunolog virolog oncolog
buy thesi base street
underappreci strength humira
formul patent combin patent
litig timelin give us confid
see us biosimilar
optimist commerci potenti
next-gener immunolog
signific negoti leverag biosimilar
develop think like lead
patent settlement push biosimilar
launch
price object po base blend valuat risk-adjust dcf
target price-to-earnings multipl non-gaap ep estim
assum wacc termin growth rate believ dcf assumpt
reason minim contribut pipelin
valid late-stag clinic studi histor trade discount peer
price-to-earnings owe humira biosimilar risk multipl expand
last month believ warrant base humira settlement pipelin
readout risk earlier-than-anticip launch humira biosimilar us
clinic pipelin failur
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
